## **VITAMIN A**

	Indication	<ul> <li>Treatment of deficiency         <ul> <li>May be indicated in neonatal cholestasis<sup>1</sup> or short bowel syndrome<sup>2</sup></li> </ul> </li> <li>Prevention of deficiency in preterm and LBW neonates<sup>3,4</sup> when *Pentavite® unavailable</li> </ul>			
ORAL	Presentation	Oral solution: 5000 units in 0.2 mL     O All doses presented in units as retinol palmitate			
	Dosage <sup>5</sup> (treatment)	<ul> <li>5000 units daily</li> <li>If prescribed concomitantly with *Pentavite® <ul> <li>2500 units daily</li> </ul> </li> </ul>			
	<b>Dosage</b> (prevention)	5000 units twice a week			
	Preparation	Draw up prescribed dose into oral/enteral syringe			
	Administration	<ul> <li>Oral/OGT/NGT with feeds to improve absorption<sup>3</sup></li> </ul>			
	Special considerations	<ul> <li>Dosage is consensus based (limited evidence)</li> <li>Criteria for deficiency prevention <ul> <li>Birth gestation less than 32 weeks</li> <li>Day 7 of life and tolerating EBM or PDHM</li> <li>Not receiving PN</li> <li>Cease at 32 weeks corrected gestational age</li> </ul> </li> <li>Supplementation may be associated with decreased risk of developing CNLD in preterm and LBW neonates<sup>6,7</sup></li> <li>Vitamin A can be presented as units, IU or microgram RAE <ul> <li>1 microgram RAE=3.33 units of retinol</li> </ul> </li> <li>Other sources of vitamin A <ul> <li>*Pentavite® contains 390 microgram RAE</li> <li>Milk fortification may contain varied concentrations</li> </ul> </li> </ul>			
	Monitoring	<ul> <li>Treatment dose (to prevent hypervitaminosis and associated hepatotoxicity<sup>5</sup>)</li> <li>Vitamin A levels every 1–2 months until stabilised within range, then every 3–6 months (at SMO's discretion)<sup>8</sup></li> <li>Prevention dose         <ul> <li>Not routinely required</li> </ul> </li> </ul>			
	Compatibility	Not applicable			
	Incompatibility				
	Interactions   • Nil significant (at recommended dose)				
	Stability <sup>9</sup>	<ul> <li>ility<sup>9</sup></li> <li>Store below 25 °C. Protect from light</li> <li>Discard 4 weeks after opening or as per local policy</li> </ul>			
	Side effects	<ul> <li>Rare         <ul> <li>Digestive: abdominal discomfort<sup>4</sup></li> <li>Lymphatic: oedema<sup>4</sup>, bulging fontanelle<sup>4</sup></li> <li>Musculo-skeletal: bone pain<sup>4,10</sup></li> <li>Nervous: irritability<sup>4</sup></li> </ul> </li> </ul>			
	Actions	<ul> <li>Fat-soluble vitamin<sup>4,10</sup></li> <li>Promotes growth in lung and retinal epithelial cells<sup>10,11</sup></li> <li>Important for reproductive functions and immune system development<sup>10</sup></li> </ul>			
	Abbreviations	*Pentavite® refers to Pentavite® (Multivitamin liquid for infants 0–3 years) CNLD: chronic neonatal lung disease, EBM: expressed breast milk, IU: international units, LBW: low birth weight, NGT: nasogastric tube, OGT: orogastric tube, PDHM: pasteurised donor human milk, PN: parenteral nutrition, RAE: retinol activity equivalents, SMO: most senior medical officer			
	Keywords	cholestasis, cholestatic liver disease, neonatal medicine, neonatal monograph, pentavite, retinol, short bowel syndrome, vitamin a, vitamin a deficiency, vitamin supplementation			



The Queensland Clinical Guideline *Neonatal Medicines* is integral to and should be read in conjunction with this monograph. Refer to the disclaimer. Destroy all printed copies of this monograph after use.

## References

1. Shneider BL, Magee JC, Bezerra JA, Haber B, Karpen SJ, Raghunathan T, et al. Efficacy of fat-soluble vitamin supplementation in infants with biliary atresia. Pediatrics. 2012; 130(3):e607-14 DOI:10.1542/peds.2011-1423.

2. Cernat E, Corlett C, Iglesias N, Onyeador N, Steele J, Batra A. Short bowel syndrome in infancy: recent advances and practical management. Frontline Gastroenterology 2021;12(7):614-21.

3. British National Formulary for Children (BNFC) online. Vitamin A. [Internet]. London: Royal Pharmaceutical Society; 2023 [cited 2023 November 21]. Available from: <u>https://www.bnf.org</u>.

4. IBM Micromedex®Neofax®. Vitamin A. [Internet]. Colorado USA: Truven Health Analytics; 2023 [cited 2023 November 21]. Available from: https://www.micromedexsolutions.com/neofax.

5. Yang CH, Perumpail BJ, Yoo ER, Ahmed A, Kerner JA. Nutritional needs and support for children with chronic liver disease. Nutrients 2017;9(10):1127.

6. Manapurath RM, Kumar M, Pathak BG, Chowdhury R, Sinha B, Choudhary T, et al. Enteral low-dose vitamin a supplementation in preterm or low birth weight infants to prevent morbidity and mortality: a systematic review and meta-analysis. Pediatrics 2022;150.

7. Huang L, Zhu D, Pang G. The effects of early vitamin A supplementation on the prevention and treatment of bronchopulmonary dysplasia in premature infants: a systematic review and meta-analysis. Translational Pediatrics 2021;10(12):3218-29.

8. Kamath BM, Alonso EM, Heubi JE, Karpen SJ, Sundaram SS, Shneider BL, et al. Fat soluble vitamin assessment and supplementation in cholestasis. Clinics in liver disease 2022;26(3):537-53.

9. Therapeutic Goods Administration (TGA). Vitamin A product information. [Internet]. Canberra: Australian Government; July 2019 [cited 2023 October 16]. Available from: <u>https://www.tga.gov.au</u>.

10. Darlow BA, Graham PJ, Rojas-Reyes MX. Vitamin A supplementation to prevent mortality and short- and long-term morbidity in very low birth weight infants. Cochrane Database of Systematic Reviews. [Internet]. 2016, [cited 2023 October 16]. Issue Art No.: CD000501. DOI:10.1002/14651858.CD000501.pub4.

11. Embleton ND, Jennifer Moltu S, Lapillonne A, van den Akker CHP, Carnielli V, Fusch C, et al. Enteral nutrition in preterm infants (2022): a position paper from the ESPGHAN committee on nutrition and invited experts. Journal of Pediatric Gastroenterology and Nutrition 2023;76(2):248-68.

## **Document history**

ID number	Effective	Review	Summary of updates
NMedQ24.116-V1-R29	22/07/2024	22/07/2029	Endorsed by Queensland Neonatal Services Advisory Group (QNSAG)

## QR code



